AbbVie (NYSE:ABBV) Releases Quarterly Earnings Results, Beats Expectations By $0.09 EPS

AbbVie (NYSE:ABBV) posted its earnings results on Friday. The company reported $3.82 EPS for the quarter, beating analysts’ consensus estimates of $3.73 by $0.09, FiscalAI reports. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The firm had revenue of $17.40 billion for the quarter, compared to the consensus estimate of $17.32 billion. During the same period last year, the firm posted $1.86 EPS. The company’s revenue was up 10.3% on a year-over-year basis.

Here are the key takeaways from AbbVie’s conference call:

• AbbVie raised its full-year outlook after third-quarter adjusted EPS of $3.82 and revenue of $17.4 billion exceeded expectations. Full-year revenue guidance increased by $200 million to approximately $67.8 billion, while adjusted EPS guidance rose to $13.95–$13.99.
• Immunology remained the primary growth engine, with SKYRIZI sales up 22.9% operationally to nearly $5.8 billion and RINVOQ sales up 24.3% to $2.7 billion. AbbVie expects further momentum from SKYRIZI’s newly approved subcutaneous Crohn’s induction regimen and potential RINVOQ approvals in vitiligo and alopecia areata.
• AbbVie highlighted several pipeline and portfolio catalysts, including FDA approval of JUVMO for Parkinson’s disease, positive phase III data for etentamig in multiple myeloma, and a 51% reduction in disease progression or death with EPKINLY plus R-CHOP in frontline DLBCL. Regulatory submissions and potential approvals are expected across these programs in 2027.
• Legacy and pressured businesses continued to weigh on results: HUMIRA sales fell 30.6% due to biosimilar competition, IMBRUVICA declined 26.1% amid IRA pricing and share pressure, and aesthetics revenue fell 1.8% as JUVÉDERM remained weak. AbbVie also expects a gradual JUVMO launch because broader Medicare coverage is not expected until 2028.
• Strong cash generation supported a 5.2% quarterly dividend increase to $1.82 per share and continued business-development capacity. Management said future deals are likely to be bolt-on acquisitions focused on differentiated assets in immunology, neuroscience, oncology, and obesity rather than another transformational transaction.

AbbVie Price Performance

NYSE:ABBV traded up $3.03 during trading hours on Friday, reaching $293.82. The company’s stock had a trading volume of 3,687,609 shares, compared to its average volume of 6,313,799. AbbVie has a one year low of $190.75 and a one year high of $298.74. The company has a market cap of $519.12 billion, a price-to-earnings ratio of 83.02, a price-to-earnings-growth ratio of 1.31 and a beta of 0.24. The business’s 50-day moving average is $268.69 and its 200-day moving average is $236.86.

AbbVie Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 2.4%. The ex-dividend date of this dividend is Thursday, October 15th. AbbVie’s payout ratio is presently 195.48%.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie reported adjusted earnings of $3.82 per share, above the roughly $3.73–$3.74 consensus, while revenue rose 10.3% year over year to $17.404 billion, also topping estimates. AbbVie Reports Third-Quarter 2026 Financial Results
• Positive Sentiment: The immunology portfolio was the primary growth engine: Skyrizi revenue reached $5.776 billion and Rinvoq generated $2.706 billion, helping total immunology revenue grow 16.3%. Neuroscience revenue also rose 19.4%, led by Vraylar, Botox Therapeutic, and migraine treatments. ABBV Beats on Q3 Earnings and Sales
• Positive Sentiment: Management raised 2026 adjusted EPS guidance from $13.76–$13.96 to $13.95–$13.99. AbbVie also announced a 5.2% increase to its 2027 dividend, supporting the stock’s income-investment appeal.
• Positive Sentiment: QULIPTA outperformed topiramate in a Phase 3 migraine-prevention study, potentially strengthening AbbVie’s neuroscience pipeline and future growth prospects. QULIPTA Phase 3 Migraine Study
• Neutral Sentiment: AbbVie completed its acquisition of Apogee Therapeutics, deepening its immunology pipeline. The deal may improve long-term growth, but integration and development costs remain considerations.
• Negative Sentiment: Humira revenue fell 31.2% to $683 million as biosimilar competition continued. Aesthetics revenue also declined 1.4%, while the stock’s elevated valuation leaves less room for execution misses.

Insider Activity at AbbVie

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the transaction, the executive vice president owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 0.06% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have issued reports on ABBV. Argus raised their price target on shares of AbbVie from $250.00 to $270.00 in a research note on Tuesday, August 4th. Scotiabank upped their price target on AbbVie from $280.00 to $320.00 and gave the stock an “outperform” rating in a report on Tuesday, October 6th. BMO Capital Markets increased their target price on AbbVie from $258.00 to $300.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. Erste Group Bank upgraded AbbVie from a “hold” rating to a “buy” rating in a research report on Wednesday, August 5th. Finally, Morgan Stanley increased their price objective on shares of AbbVie from $296.00 to $310.00 and gave the stock an “overweight” rating in a report on Wednesday, October 7th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $279.86.

AbbVie Company Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.